Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiTE in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection
NCT07689578Phase 4Recruiting
- Sponsor
- Terns Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of linvoseltamab in chronic antibody-mediated rejection (cAMR), sponsored by Terns Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events at 1 year. Started Jul 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
chronic antibody-mediated rejection (cAMR)
Beyond the preview
Go deeper on NCT07689578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689578.